Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: Versus alfacalcidol

Modern Rheumatology

Volumn 18, Issue 3, 2008, Pages 271-276

  Takeda, Seiji ^a,b   Kaneoka, Hidetoshi ^a   Saito, Takao ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hakusuien Kasuga Hospital   (Japan)

Author keywords

Alendronate; Alfacalcidol; Bone mineral density; Glucocorticoid; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; GLUCOCORTICOID; PREDNISOLONE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; FEMALE; HUMAN; JAPANESE; LONG TERM CARE; LUMBAR VERTEBRA; MAXIMUM PERMISSIBLE DOSE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC DISEASE; TREATMENT DURATION;

ADULT; ALENDRONATE; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; JAPAN; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 46549085919     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0055-y     Document Type: Article

References (26)

1. Cohen D, Adachi JD. The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol. 2004;88:337-49.
2. American College of Rheumatology Task Force on osteoporosis guidelines recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 1996;39:1797-801.
3. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med. 1998;244:271-92.
4. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum. 2000;29:228-52.
5. American College of Rheumatology ad hoc committee on glucocorticoid-induced osteoporosis recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Update. Arthritis Rheum. 2001;44:1496-503.
6. Brown JP, Josse RG. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J. 2002;167:1S-34S.
7. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicians Glucocorticoid-induced osteoporosis: Guidelines for prevention and treatment. Royal College of Physicians, London 2002.
8. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-6.
9. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005;23:105-9.
10. Tanaka Y, Okada Y, Nakamura T. Inter- and intracellular signaling in secondary osteoporosis. J Bone Miner Metab. 2003;21:61-6.
11. Barrett-Connor E, Siris ES, Wehren LE, Miller PD, Abbott TA, Berger ML, Santora AC, Sherwood LM. Osteoporosis and fracture risk n female patients of different ethnic groups. J Bone Miner Res. 2005;20:185-94.
12. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339:292-9.
13. Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkes CJ, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int. 1999;9(1):75-81.
14. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44(1):202-11.
15. de Nijs RNJ, Jacobs JWG, Lems WF, Laan RFJ, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med. 2006;355:675-84.
16. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum. 1985;28:361-8.
17. McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:704-9.
18. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses. Rheumatol. 2000;39:1383-9.
19. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279-84.
20. van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis. Osteoporos Int. 2002;13:777-87.
21. McKenzie R, Reynolds JC, O'Fallon A, Dale J, Deloria M, Blackwelder W, Straus S. Decreased bone mineral density during low dose glucocorticoid administration in a randomized, placebo controlled trial. J Rheumatol. 2000;27:2222-6.
22. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, et al. A placebo-controlled, single-blinded study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocrine J. 1998;45(2):191-201.
23. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int. 1999;10:183-92.
24. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese female patients with osteoporosis: A 3-year follow-up study. J Bone Miner Metab. 2004;22:462-8.
25. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 1993;92:2577-86.
26. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 2003;33:150-8.